<DOC>
	<DOCNO>NCT03008109</DOCNO>
	<brief_summary>EGFR Tyrosine-Kinase Inhibitor monotherapy widely use treatment patient EGFR mutation-positive Non-small cell lung cancer ( NSCLC ) , In despite benefit PFS （progression-free survival） , OS （ overall survival） limit extend . This study aim observe safety efficacy combination anti-angiogenic drug recombinant human-endostatin EGFR TKI , find new strategy may extend PFS OS tolerate toxicity .</brief_summary>
	<brief_title>Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor—Tyrosine-Kinase Inhibitor） Treatment EGFR Mutation-positive NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Advanced NSCLC , EGFR mutation positive , PS（performance status） 02 , Patients require one measurable lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>EGFR-TKI</keyword>
	<keyword>Recombinant human endostatin</keyword>
</DOC>